

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/33232> holds various files of this Leiden University dissertation.

**Author:** Kühnast, Susan,

**Title:** Innovative pharmaceutical interventions in experimental atherosclerosis : focusing on the contribution of non-HDL-C versus HDL-C

**Issue Date:** 2015-06-11



**Innovative Pharmaceutical Interventions in Experimental Atherosclerosis:**  
Focusing on the Contribution of non-HDL-C versus HDL-C

## **Colophon**

© S. Kühnast, 2015.

All rights reserved. No part of this thesis may be reproduced or transmitted in any form without written permission of the publisher and copyright owner, or where appropriate, the publishers of the articles.

ISBN: 978-94-6108-977-9

Cover Design: It's Ink, Parys, South Africa

Layout and printing: Gildeprint, Enschede

The printing of this thesis was kindly supported by:

Daan Traas fonds

TNO, Metabolic Health Research

**Innovative Pharmaceutical Interventions in Experimental Atherosclerosis:**  
Focusing on the Contribution of non-HDL-C versus HDL-C

PROEFSCHRIFT

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op donderdag 11 juni 2015  
klokke 11:15 uur

door

**Susan Kühnast**

geboren te Ermelo, Zuid-Afrika  
in 1980

## **Promotiecommissie**

<b>Promotor:</b>	Prof. Dr. J.W. Jukema
<b>Co-promotores:</b>	Dr. J.M.G. Princen (TNO, Leiden) Dr. J.W.A. van der Hoorn (TNO, Leiden)
<b>Overige leden:</b>	Prof. Dr. Ir. L.M. Havekes Prof. Dr. P.C.N. Rensen Prof. Dr. E.S.G. Stroes (AMC, Amsterdam) Prof. Dr. J.A. Kuivenhoven (UMCG, Groningen)

The studies presented in this thesis were performed at the Gaubius Laboratory of TNO, Leiden, the Netherlands. The research was in part financially supported by Novartis, Sanofi-Aventis and Regeneron.

## Table of Contents

<b>Chapter 1</b>	<b>7</b>
General introduction.	
<b>Chapter 2</b>	<b>21</b>
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. <i>J Hypertens.</i> 2012 Jan;30(1):107-16.	
<b>Chapter 3</b>	<b>43</b>
Niacin reduces atherosclerosis development in APOE*3Leiden.CETP mice mainly by reducing non-HDL-cholesterol. <i>PLoS One.</i> 2013 Jun 19;8(6):e66467.	
<b>Chapter 4</b>	<b>69</b>
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. <i>Eur Heart J.</i> 2015 Jan 1;36(1):39-50.	
<b>Chapter 5</b>	<b>93</b>
Anacetrapib reduces (V)LDL-cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. <i>Submitted.</i>	
<b>Chapter 6</b>	<b>117</b>
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. <i>J Lipid Res.</i> 2014 Oct;55(10):2103-12.	
<b>Chapter 7</b>	<b>143</b>
Innovative pharmaceutical interventions in cardiovascular disease: focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising - A systematic review and meta-analysis of relevant preclinical studies and clinical trials. <i>Accepted – Eur J Pharmacol.</i>	
<b>Chapter 8</b>	<b>179</b>
General discussion and future perspectives	
<b>Summary</b>	<b>195</b>
<b>Samenvatting</b>	<b>199</b>
<b>List of Publications</b>	<b>203</b>
<b>Curriculum Vitae</b>	<b>205</b>
<b>Dankwoord</b>	<b>207</b>

